secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001477932-25-003852
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q1 revenue $0.25M (+44% YoY); first commercial revenue from CE-marked Nu.Q NETs in Europe
--------------------------------------------------------------------------------

- Revenue of ~$0.25M in Q1 2025, up 44% from Q1 2024; first revenue from regulated CE-marked Nu.Q NETs automated product.
- Net cash used in ops averaged $1.4M/month, down ~50% vs Q1 2024; cash balance $2.6M at March 31, 2025.
- Post-quarter closed $6.25M convertible loan note (24-month, 6-month repayment holiday).
- Confidential licensing discussions with >10 companies; combined market cap of seven >$600B.
- Goal to be cash neutral on full-year 2025 basis via licensing receipts and cost reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793225003852/0001477932-25-003852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793225003852/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-003852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer